BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
1-Year Return
36.47%
This Quarter Return
+43.59%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$1.04B
AUM Growth
+$149M
(+17%)
Cap. Flow
-$78.9M
Cap. Flow
% of AUM
-7.56%
Top 10 Holdings %
Top 10 Hldgs %
81.6%
Holding
33
New
2
Increased
4
Reduced
3
Closed
6
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$75.1M |
| 2 |
Revolution Medicines
RVMD
|
+$31.9M |
| 3 |
Annexon
ANNX
|
+$10.7M |
| 4 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$4.87M |
| 5 |
X4 Pharmaceuticals
XFOR
|
+$801K |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$71.2M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.9M |
| 3 |
Pharvaris
PHVS
|
+$24.7M |
| 4 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
+$22.2M |
| 5 |
Natera
NTRA
|
+$18.8M |
Sector Composition
| 1 | Healthcare | 98.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xilio Therapeutics
XLO
$38.2M
| $1.54M | 0.15% |
2,805,413
| – | – |
|
27
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$62.3M
| $313K | 0.03% |
100,000
| – | – |
|
|
28
Crinetics Pharmaceuticals
CRNX
$3.2B
| – | – |
-1,275,552
| Closed | -$37.9M |
|
29
Dynavax Technologies
DVAX
$1.1B
| – | – |
-915,000
| Closed | -$13.5M |
|
|
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-3,081,307
| Closed | -$71.2M |
|
|
TVRD
31
Tvardi Therapeutics, Inc. Common Stock
TVRD
$318M
| – | – |
-657
| Closed | -$39.7K |
|
|
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-913,969
| Closed | -$13.6M |
|
|
EQRX
33
DELISTED
EQRx, Inc. Common Stock
EQRX
| – | – |
-10,003,573
| Closed | -$22.2M |
|